Tag Archives: tirzepatide

Lilly Ph1b Elora + Tirzep Preliminary Data; Ribo and Madrigal First siRNA Development Milestone; UpDoc FDA Clearance

Three cardiometabolic-related news items have been observed: Lilly released preliminary data from its Ph1b eloralintide + tirzepatide combination study (view abstract), Ribo and Madrigal reached the first milestone in their MASH siRNA partnership (view press release), and UpDoc received FDA clearance for its physician-grade clinical AI platform (view press release ). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Medicare GLP-1 Bridge Program Initiates; Tandem’s t:slim Pump and Abbott’s FreeStyle Libre 3+ Launch in Select UK/EU Markets; Hengrui Posts Ph3 Oral Ribupatide Study in China; Terrestrial Bio Doses First Patient with Needle-Free Sema Patch Technology; Tufts Health Eliminates Coverage for Dexcom CGMs

A series of cardiometabolic-related news items has been observed from The Obesity Action Coalition, Hengrui, Terrestrial Bio, Tandem Diabetes Care, and Tufts Health Direct. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Insulet Appoints Chief R&D Officer; FDA to Review Sandoz Generic Tirzepatide; Kailera Appoints Chief Affairs Officer; Resalis Doses First Patient in Ph1b Obesity Study

A series of cardiometabolic-related news items have been observed from Insulet, FDA/Sandoz, Kailera Therapeutics, and Resalis Therapeutics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo AMAZE 7 and 13 Zenagamtide Studies; New Ph2 UBT251 Study; Vivani Ph1 Sema Implant Study; TWL Virtual Tirzepatide Assessment; Anodyne $12.6M Series A

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Vivani Medical, Top Weight Loss Med, and Anodyne Nanotech. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Structure Initiates Pivotal Aleniglipron Studies; MiniMed Flex US Launch; FiberSense CGM CE Mark; FDA Compounding Warning Letters

A series of cardiometabolic-related news items has been observed from Structure Therapeutics, MiniMed, FiberSense, and FDA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

ADA 2026 Key Press Releases (June 5)

On the first day of the ADA 2026 conference, six cardiometabolic-related news items have been observed from Tandem, Veru, Gan & Lee, Cigna, Bayer, and Structure Therapeutics. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.

Already a member? Log in here

Another FDA Official Fired; AZ’s Baxdrostat Approved for HTN; Dexcom Flex to Launch in Germany; May CHMP Agenda

A series of cardiometabolic-related news items has been observed from FDA, AstraZeneca, Dexcom, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

ProRx FDA Warning Letter; Lilly Partners with UNICEF

Two cardiometabolic-related news items have been observed: FDA issued a warning letter to ProRx regarding GLP-1RA compounding (view FDA letter) and Lilly partnered with UNICEF (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Makary Resigns; Novo OASIS 4 Data; Altimmune Q1 ’26 Earnings; Lilly SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN Full Data; Insulet Initiates O6 vs. O5 Study

A series of cardiometabolic-related news items has been observed from FDA, Novo Nordisk, Altimmune, Lilly, and Insulet. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly, Viking, and Merck Q1 ’26 Earnings; FDA Semaglutide and Tirzepatide Compounding Exclusions

A series of cardiometabolic-related news items has been observed from Lilly, Viking Therapeutics, Merck, and FDA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here